Facundo Galceran

Facundo Galceran

Auto-generated profile, based on publicly available information

Facundo Galceran

Instituto de Fisiologia, Biologia Molecular y Neurociencias (IFIBYNE), Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2026 in Science Advances
Verified
Journal Article
Open access
ABAnna V. Bulankina
Anna V. Bulankina
RRRebecca Michaela Richter
Rebecca Michaela Richter
JNJames H. Nettles
James H. Nettles
DYDaisuke Yamane
Daisuke Yamane
CGChristian Grimm
Christian Grimm
CWChristoph Welsch
Christoph Welsch
Phospholipids are essential for RNA virus replication, yet their role in modulating conformational dynamics of membrane-associated viral proteins remains poorly understood. For NS5A, a key replication factor of hepatitis C virus, previous crystallographic models fail to capture the lipid-driven conformational mechanics we uncover here. Using structural informatics and biochemical probing of pharmacophore-guided mutants in defined lipid environments, we evaluated competing NS5A domain 1 dimerization models. Our data reveal an alternative membrane-specific fold stabilized by polyproline hinges and phospholipids (PIPs) such as phosphatidylinositol-4-phosphate, a host lipid enriched at replication membranes. PIP binding promotes a conformational switch that drives dimerization, linking lipid sensing to membrane remodeling and host factor recruitment. This reciprocal mechanism—where a lipid allosterically modulates a viral protein that reshapes membranes—is blocked by the antiviral pibrentasvir. These findings define a lipid-driven structural switch that governs NS5A pleiotropy and highlight dynamic lipid-protein interfaces as targets for antiviral intervention.

6 December 2023 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
CRChantal Reigada
Chantal Reigada
FDFabio Digirolamo
Fabio Digirolamo
FGFacundo Galceran
Facundo Galceran
MSMelisa Saye
Melisa Saye
CCCarolina Carrillo
Carolina Carrillo
CPClaudio Alejandro Pereira
Claudio Alejandro Pereira

11 July 2024 in Journal of Biological Chemistry
Verified
Journal Article
Open access
LGLissy Z.F. Gross
Lissy Z.F. Gross
AWAngelika F. Winkel
Angelika F. Winkel
FGFacundo Galceran
Facundo Galceran
JSJörg O. Schulze
Jörg O. Schulze
WFWolfgang Fröhner
Wolfgang Fröhner
RBRicardo M. Biondi
Ricardo M. Biondi
The PKC-related kinases (PRKs, also termed PKNs) are important in cell migration, cancer, hepatitis C infection, and nutrient sensing. They belong to a group of protein kinases called AGC kinases that share common features like a C-terminal extension to the catalytic domain comprising a hydrophobic motif. PRKs are regulated by N-terminal domains, a pseudosubstrate sequence, Rho-binding domains, and a C2 domain involved in inhibition and dimerization, while Rho and lipids are activators. We investigated the allosteric regulation of PRK2 and its interaction with its upstream kinase PDK1 using a chemical biology approach. We confirmed the phosphoinositide-dependent protein kinase 1 (PDK1)-interacting fragment (PIF)-mediated docking interaction of PRK2 with PDK1 and showed that this interaction can be modulated allosterically. We showed that the polypeptide PIFtide and a small compound binding to the PIF-pocket of PRK2 were allosteric activators, by displacing the pseudosubstrate PKL region from the active site. In addition, a small compound binding to the PIF-pocket allosterically inhibited the catalytic activity of PRK2. Together, we confirmed the docking interaction and allostery between PRK2 and PDK1 and described an allosteric communication between the PIF-pocket and the active site of PRK2, both modulating the conformation of the ATP-binding site and the pseudosubstrate PKL-binding site. Our study highlights the allosteric modulation of the activity and the conformation of PRK2 in addition to the existence of at least two different complexes between PRK2 and its upstream kinase PDK1. Finally, the study highlights the potential for developing allosteric drugs to modulate PRK2 kinase conformations and catalytic activity.